|
|
Volumn 136, Issue 1, 2010, Pages 15-20
|
|
Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMYLOID BETA PROTEIN[1-40];
AMYLOID PRECURSOR PROTEIN;
ANTERIOR PHARYNX DEFECTIVE 1 PROTEIN;
ASP 1702;
BEGACESTAT;
BETA SECRETASE;
BETA SECRETASE 1;
BETA SECRETASE INHIBITOR;
BMS 708163;
CD19 ANTIGEN;
CHF 5074;
CLIOQUINOL;
CTS 21166;
E 2012;
E 2212;
ELND 005;
ELND 006;
FLURBIPROFEN;
GERO 46;
HOMOTAURINE;
HPP 854;
N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE;
NIC 5 15;
NOOTROPIC AGENT;
NOTCH RECEPTOR;
NRM 8499;
PBT 2;
PF 4494700;
PRESENILIN 2;
SEMAGACESTAT;
TARENFLURBIL;
UNCLASSIFIED DRUG;
ALANINE;
AMYLOID BETA PROTEIN;
ASPARTIC PROTEINASE;
AZEPINE DERIVATIVE;
BACE1 PROTEIN, HUMAN;
ENZYME INHIBITOR;
N2-((2S)-2-(3,5-DIFLUOROPHENYL)-2-HYDROXYETHANOYL)-N1-((7S)-5-METHYL-6-OXO-6,7-DIHYDRO-5H-DIBENZO(B,D)AZEPIN-7-YL)-L-ALANINAMIDE;
SECRETASE;
TAURINE;
ALZHEIMER DISEASE;
AREA UNDER THE CURVE;
CEREBROSPINAL FLUID;
CONTROLLED STUDY;
IC 50;
IN VITRO STUDY;
IN VIVO STUDY;
PROTEIN BLOOD LEVEL;
PROTEIN DOMAIN;
PROTEIN FOLDING;
REVIEW;
ANALOGS AND DERIVATIVES;
ANTAGONISTS AND INHIBITORS;
DRUG DESIGN;
HUMAN;
METABOLISM;
ALANINE;
ALZHEIMER DISEASE;
AMYLOID BETA-PROTEIN;
AMYLOID BETA-PROTEIN PRECURSOR;
AMYLOID PRECURSOR PROTEIN SECRETASES;
ASPARTIC ACID ENDOPEPTIDASES;
AZEPINES;
DRUG DESIGN;
ENZYME INHIBITORS;
FLURBIPROFEN;
HUMANS;
TAURINE;
AMYLOID BETA-PEPTIDES;
|
|
EID: 77956492864
PISSN: 00155691
EISSN: 13478397
Source Type: Journal
DOI: 10.1254/fpj.136.15 Document Type: Review |
|
Times cited : (4)
|
|
References (41)
|
